Up-regulation of ST18 in pemphigus vulgaris drives a self-amplifying p53-dependent pathomechanism resulting in decreased desmoglein 3 expression.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
08 04 2022
08 04 2022
Historique:
received:
24
11
2021
accepted:
14
03
2022
entrez:
9
4
2022
pubmed:
10
4
2022
medline:
13
4
2022
Statut:
epublish
Résumé
Pemphigus vulgaris (PV) is a life-threatening autoimmune mucocutaneous blistering disease which is to a large extent genetically determined, and results, at least in part, from the deleterious activity of autoantibodies directed against desmoglein (DSG)3, a prominent intra-epidermal adhesion molecule. Those autoantibodies lead to decreased membranal DSG3 expression in keratinocytes (KCs), thereby destabilizing cell-cell adhesion within the epidermis and leading to blister formation. We previously showed that rs17315309, a strong risk variant for PV within the promoter of the ST18 transcription factor gene, promotes epidermal ST18 up-regulation in a p53/p63-dependent manner. Accordingly, ST18 was found to be overexpressed in the skin of PV patients. Increased ST18 expression was then shown to markedly augment PV autoantibodies-mediated loss of KCs cohesion. Here, we demonstrate that ST18 overexpression significantly increases autoantibody-mediated DSG3 down-regulation in keratinocytes. In addition, DSG3 decreased expression boosts p53 function through p38 mitogen-activated protein kinase (p38MAPK) activation and dramatically augments p53-dependent ST18 promoter activity. Finally, the PV risk variant rs17315309 is associated with increased p53 expression in PV skin. Taken collectively, these observations reveal a novel self-amplifying pathomechanism involving ST18, DSG3, p38 and p53, capable of perpetuating disease activity, and therefore indicative of novel actionable molecular targets in PV.
Identifiants
pubmed: 35396567
doi: 10.1038/s41598-022-09951-x
pii: 10.1038/s41598-022-09951-x
pmc: PMC8993920
doi:
Substances chimiques
Autoantibodies
0
DSG3 protein, human
0
Desmoglein 3
0
Repressor Proteins
0
ST18 protein, human
0
TP53 protein, human
0
Tumor Suppressor Protein p53
0
p38 Mitogen-Activated Protein Kinases
EC 2.7.11.24
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
5958Informations de copyright
© 2022. The Author(s).
Références
Front Immunol. 2019 Oct 15;10:2327
pubmed: 31749790
Dermatol Clin. 2011 Jul;29(3):373-80, vii
pubmed: 21605802
Exp Dermatol. 2018 Dec;27(12):1395-1398
pubmed: 30192416
Front Med (Lausanne). 2021 Aug 09;8:701809
pubmed: 34434944
Blood. 2015 Sep 17;126(12):1473-82
pubmed: 26228485
J Invest Dermatol. 2005 May;124(5):939-46
pubmed: 15854034
Immunol Res. 2018 Apr;66(2):255-270
pubmed: 29479654
Front Immunol. 2019 Apr 17;10:770
pubmed: 31057535
J Biol Chem. 2005 Jun 24;280(25):23778-84
pubmed: 15840580
Front Immunol. 2018 Mar 19;9:528
pubmed: 29616033
JID Innov. 2021 Feb 20;1(1):100004
pubmed: 34909708
Front Med (Lausanne). 2018 Aug 14;5:226
pubmed: 30155467
J Biol Chem. 2019 Mar 22;294(12):4520-4528
pubmed: 30692201
J Immunol. 2003 Feb 15;170(4):2170-8
pubmed: 12574390
J Clin Invest. 2015 Jun;125(6):2228-33
pubmed: 25893595
PLoS Genet. 2016 May 05;12(5):e1006008
pubmed: 27148741
Genet Med. 2020 Jul;22(7):1227-1234
pubmed: 32336749
Clin Rev Allergy Immunol. 2018 Feb;54(1):1-25
pubmed: 29313220
J Invest Dermatol. 2018 Jan;138(1):32-37
pubmed: 29037765
J Invest Dermatol. 2016 Jan;136(1):301-10
pubmed: 26763450
Genet Mol Biol. 2020;43(3):e20190369
pubmed: 32639508
J Dermatol. 2014 Apr;41(4):353-4
pubmed: 24612320
J Allergy Clin Immunol. 2020 Apr;145(4):1031-1047
pubmed: 32272980
Cancer Res. 2000 May 1;60(9):2464-72
pubmed: 10811125
FASEB J. 2008 Nov;22(11):3956-67
pubmed: 18676404
Am J Physiol Lung Cell Mol Physiol. 2015 Apr 15;308(8):L776-87
pubmed: 25713322
Cell Death Dis. 2019 Oct 3;10(10):750
pubmed: 31582719
Br J Dermatol. 2021 Jun;184(6):1153-1160
pubmed: 33205400
Biochim Biophys Acta. 2013 Aug;1830(8):4053-64
pubmed: 23583370
J Invest Dermatol. 2012 Jul;132(7):1798-805
pubmed: 22437316
Lancet. 2019 Sep 7;394(10201):882-894
pubmed: 31498102
Exp Dermatol. 2016 Nov;25(11):839-846
pubmed: 27305362
Science. 1991 Jun 21;252(5013):1708-11
pubmed: 2047879
Br J Dermatol. 2017 Dec;177(6):1612-1618
pubmed: 28600798
Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12855-60
pubmed: 16908851